MSD’s Keytruda shows benefit in oesophageal cancer trial
MSD's Keytruda has shown promise in a late-stage trial testing its safety and efficacy in patients with advanced or metastatic esophageal or esophagogastric junction carcinoma. [...]
Thu, Nov 15, 2018
Final NICE green light for Pfizer’s Mylotarg
Cost regulators for the NHS in England and Wales have now published final guidelines recommending Mylotarg, alongside daunorubicin and cytarabine, as an option for untreated de novo CD33-positive acute myeloid leukaemia (AML). [...]
Thu, Nov 15, 2018
NIHR streams £5m into global infectious diseases research
The National Institute for Health Research is streaming £5 million of global health funding into research looking at how infectious diseases spread and develop into epidemics in low- and middle-income countries. [...]
Thu, Nov 15, 2018
Ipsen’s Cabometyx wins EU nod for liver cancer
Ipsen's Cabometyx can now be used as monotherapy to treat certain patients with liver cancer following a green light from regulators in Europe. [...]
Thu, Nov 15, 2018

 

The Learning  Partnership